25 XP   0   0   10

Puma Biotechnology Inc
Buy, Hold or Sell?

Let's analyse Puma Biotechnology Inc together

PenkeI guess you are interested in Puma Biotechnology Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Puma Biotechnology Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Puma Biotechnology Inc

I send you an email if I find something interesting about Puma Biotechnology Inc.

Quick analysis of Puma Biotechnology Inc (30 sec.)










What can you expect buying and holding a share of Puma Biotechnology Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.11
Expected worth in 1 year
$1.77
How sure are you?
45.0%

+ What do you gain per year?

Total Gains per Share
$0.66
Return On Investment
13.2%

For what price can you sell your share?

Current Price per Share
$5.01
Expected price per share
$3.66 - $6.055
How sure are you?
50%

1. Valuation of Puma Biotechnology Inc (5 min.)




Live pricePrice per Share (EOD)

$5.01

Intrinsic Value Per Share

$-2.44 - $9.99

Total Value Per Share

$-1.34 - $11.10

2. Growth of Puma Biotechnology Inc (5 min.)




Is Puma Biotechnology Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$53.4m$17.6m$19.4m52.4%

How much money is Puma Biotechnology Inc making?

Current yearPrevious yearGrowGrow %
Making money$5.3m$2k$5.3m100.0%
Net Profit Margin8.5%-0.2%--

How much money comes from the company's main activities?

3. Financial Health of Puma Biotechnology Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#469 / 1016

Most Revenue
#143 / 1016

Most Profit
#112 / 1016

Most Efficient
#123 / 1016

What can you expect buying and holding a share of Puma Biotechnology Inc? (5 min.)

Welcome investor! Puma Biotechnology Inc's management wants to use your money to grow the business. In return you get a share of Puma Biotechnology Inc.

What can you expect buying and holding a share of Puma Biotechnology Inc?

First you should know what it really means to hold a share of Puma Biotechnology Inc. And how you can make/lose money.

Speculation

The Price per Share of Puma Biotechnology Inc is $5.01. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Puma Biotechnology Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Puma Biotechnology Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.11. Based on the TTM, the Book Value Change Per Share is $0.17 per quarter. Based on the YOY, the Book Value Change Per Share is $0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Puma Biotechnology Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.255.1%0.112.2%0.000.0%-0.15-3.0%-0.63-12.5%
Usd Book Value Change Per Share0.306.1%0.173.3%0.122.5%0.020.4%-0.02-0.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.306.1%0.173.3%0.122.5%0.020.4%-0.02-0.3%
Usd Price Per Share4.33-3.40-3.08-8.25-49.08-
Price to Earnings Ratio4.25-14.08--23.74--4.75--14.87-
Price-to-Total Gains Ratio14.20-25.48--75.03-64.70-7.64-
Price to Book Ratio3.91-4.63-10.25--47.71--4.52-
Price-to-Total Gains Ratio14.20-25.48--75.03-64.70-7.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.01
Number of shares199
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.170.02
Usd Total Gains Per Share0.170.02
Gains per Quarter (199 shares)32.853.95
Gains per Year (199 shares)131.4115.80
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101311210166
2026325203222
3039438304738
4052651406354
5065764507970
6078877609586
709209070111102
80105110380126118
90118311690142134
100131413000158150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%7.05.00.058.3%8.012.00.040.0%8.032.00.020.0%8.057.00.012.3%
Book Value Change Per Share4.00.00.0100.0%10.02.00.083.3%13.07.00.065.0%18.022.00.045.0%28.034.03.043.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.065.00.0%
Total Gains per Share4.00.00.0100.0%10.02.00.083.3%13.07.00.065.0%18.022.00.045.0%28.034.03.043.1%

Fundamentals of Puma Biotechnology Inc

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Fundamental data was last updated by Penke on 2024-04-12 14:40:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Puma Biotechnology Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Puma Biotechnology Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Puma Biotechnology Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 17.0% means that $0.17 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Puma Biotechnology Inc:

  • The MRQ is 17.0%. The company is making a huge profit. +2
  • The TTM is 8.5%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ17.0%TTM8.5%+8.5%
TTM8.5%YOY-0.2%+8.7%
TTM8.5%5Y-14.7%+23.2%
5Y-14.7%10Y-51.3%+36.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.0%-199.6%+216.6%
TTM8.5%-213.0%+221.5%
YOY-0.2%-279.3%+279.1%
5Y-14.7%-438.4%+423.7%
10Y-51.3%-605.5%+554.2%
1.1.2. Return on Assets

Shows how efficient Puma Biotechnology Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Puma Biotechnology Inc to the Biotechnology industry mean.
  • 5.3% Return on Assets means that Puma Biotechnology Inc generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Puma Biotechnology Inc:

  • The MRQ is 5.3%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 2.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.3%TTM2.5%+2.8%
TTM2.5%YOY0.1%+2.4%
TTM2.5%5Y-2.9%+5.4%
5Y-2.9%10Y-14.6%+11.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3%-13.5%+18.8%
TTM2.5%-12.9%+15.4%
YOY0.1%-11.8%+11.9%
5Y-2.9%-14.1%+11.2%
10Y-14.6%-16.0%+1.4%
1.1.3. Return on Equity

Shows how efficient Puma Biotechnology Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Puma Biotechnology Inc to the Biotechnology industry mean.
  • 23.0% Return on Equity means Puma Biotechnology Inc generated $0.23 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Puma Biotechnology Inc:

  • The MRQ is 23.0%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 12.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ23.0%TTM12.6%+10.4%
TTM12.6%YOY-6.9%+19.5%
TTM12.6%5Y-20.9%+33.5%
5Y-20.9%10Y-35.5%+14.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.0%-16.9%+39.9%
TTM12.6%-16.1%+28.7%
YOY-6.9%-15.1%+8.2%
5Y-20.9%-19.9%-1.0%
10Y-35.5%-20.9%-14.6%

1.2. Operating Efficiency of Puma Biotechnology Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Puma Biotechnology Inc is operating .

  • Measures how much profit Puma Biotechnology Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Puma Biotechnology Inc to the Biotechnology industry mean.
  • An Operating Margin of 20.5% means the company generated $0.21  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Puma Biotechnology Inc:

  • The MRQ is 20.5%. The company is operating efficient. +1
  • The TTM is 14.2%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ20.5%TTM14.2%+6.3%
TTM14.2%YOY12.7%+1.5%
TTM14.2%5Y-3.1%+17.3%
5Y-3.1%10Y-45.4%+42.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.5%-295.1%+315.6%
TTM14.2%-225.8%+240.0%
YOY12.7%-288.4%+301.1%
5Y-3.1%-477.4%+474.3%
10Y-45.4%-625.6%+580.2%
1.2.2. Operating Ratio

Measures how efficient Puma Biotechnology Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.79 means that the operating costs are $0.79 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Puma Biotechnology Inc:

  • The MRQ is 0.795. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.865. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.795TTM0.865-0.070
TTM0.865YOY0.874-0.010
TTM0.8655Y1.027-0.162
5Y1.02710Y1.096-0.069
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7953.090-2.295
TTM0.8653.264-2.399
YOY0.8743.783-2.909
5Y1.0275.679-4.652
10Y1.0967.894-6.798

1.3. Liquidity of Puma Biotechnology Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Puma Biotechnology Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.57 means the company has $1.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Puma Biotechnology Inc:

  • The MRQ is 1.572. The company is able to pay all its short-term debts. +1
  • The TTM is 1.930. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.572TTM1.930-0.358
TTM1.930YOY1.839+0.091
TTM1.9305Y1.688+0.241
5Y1.68810Y3.493-1.805
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5723.914-2.342
TTM1.9304.220-2.290
YOY1.8395.388-3.549
5Y1.6886.045-4.357
10Y3.4936.406-2.913
1.3.2. Quick Ratio

Measures if Puma Biotechnology Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Puma Biotechnology Inc to the Biotechnology industry mean.
  • A Quick Ratio of 1.57 means the company can pay off $1.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Puma Biotechnology Inc:

  • The MRQ is 1.568. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.907. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.568TTM1.907-0.340
TTM1.907YOY1.678+0.229
TTM1.9075Y1.618+0.290
5Y1.61810Y4.467-2.849
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5683.572-2.004
TTM1.9073.998-2.091
YOY1.6785.390-3.712
5Y1.6185.969-4.351
10Y4.4676.287-1.820

1.4. Solvency of Puma Biotechnology Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Puma Biotechnology Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Puma Biotechnology Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.77 means that Puma Biotechnology Inc assets are financed with 76.8% credit (debt) and the remaining percentage (100% - 76.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Puma Biotechnology Inc:

  • The MRQ is 0.768. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.824. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.768TTM0.824-0.055
TTM0.824YOY0.913-0.090
TTM0.8245Y0.918-0.094
5Y0.91810Y0.634+0.284
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7680.336+0.432
TTM0.8240.334+0.490
YOY0.9130.269+0.644
5Y0.9180.366+0.552
10Y0.6340.390+0.244
1.4.2. Debt to Equity Ratio

Measures if Puma Biotechnology Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Puma Biotechnology Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 331.4% means that company has $3.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Puma Biotechnology Inc:

  • The MRQ is 3.314. The company is unable to pay all its debts with equity. -1
  • The TTM is 4.939. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.314TTM4.939-1.626
TTM4.939YOY13.288-8.348
TTM4.9395Y8.517-3.578
5Y8.51710Y4.864+3.653
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3140.382+2.932
TTM4.9390.396+4.543
YOY13.2880.335+12.953
5Y8.5170.434+8.083
10Y4.8640.465+4.399

2. Market Valuation of Puma Biotechnology Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Puma Biotechnology Inc generates.

  • Above 15 is considered overpriced but always compare Puma Biotechnology Inc to the Biotechnology industry mean.
  • A PE ratio of 4.25 means the investor is paying $4.25 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Puma Biotechnology Inc:

  • The EOD is 4.922. Based on the earnings, the company is cheap. +2
  • The MRQ is 4.254. Based on the earnings, the company is cheap. +2
  • The TTM is 14.079. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.922MRQ4.254+0.668
MRQ4.254TTM14.079-9.825
TTM14.079YOY-23.742+37.821
TTM14.0795Y-4.754+18.833
5Y-4.75410Y-14.874+10.120
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.922-2.259+7.181
MRQ4.254-2.569+6.823
TTM14.079-2.664+16.743
YOY-23.742-4.120-19.622
5Y-4.754-6.258+1.504
10Y-14.874-6.171-8.703
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Puma Biotechnology Inc:

  • The EOD is 5.800. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.013. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 4.352. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD5.800MRQ5.013+0.787
MRQ5.013TTM4.352+0.661
TTM4.352YOY18.132-13.780
TTM4.3525Y-64.801+69.153
5Y-64.80110Y-53.400-11.401
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.800-2.924+8.724
MRQ5.013-3.246+8.259
TTM4.352-3.488+7.840
YOY18.132-5.620+23.752
5Y-64.801-8.315-56.486
10Y-53.400-8.826-44.574
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Puma Biotechnology Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.91 means the investor is paying $3.91 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Puma Biotechnology Inc:

  • The EOD is 4.519. Based on the equity, the company is fair priced.
  • The MRQ is 3.906. Based on the equity, the company is fair priced.
  • The TTM is 4.635. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.519MRQ3.906+0.613
MRQ3.906TTM4.635-0.729
TTM4.635YOY10.247-5.612
TTM4.6355Y-47.714+52.349
5Y-47.71410Y-4.523-43.190
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.5191.851+2.668
MRQ3.9062.090+1.816
TTM4.6352.095+2.540
YOY10.2472.844+7.403
5Y-47.7143.466-51.180
10Y-4.5233.815-8.338
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Puma Biotechnology Inc.

3.1. Institutions holding Puma Biotechnology Inc

Institutions are holding 61.44% of the shares of Puma Biotechnology Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc7.8870.00043802081296880.787
2023-12-31Millennium Management LLC6.56390.00593164249809002.6238
2023-12-31Camber Capital Management LLC5.81860.30952805000-1430000-33.7662
2023-12-31Acadian Asset Management LLC3.97720.03221917274592743.1902
2023-12-31Athyrium Capital Management LP3.717511.2746179211400
2023-12-31Eversept Partners, LLC3.51610.64481695021138720.8251
2023-12-31Renaissance Technologies Corp3.47090.01121673213-53389-3.0921
2023-12-31BlackRock Inc3.20390.00021544532688214.6636
2023-12-31Great Point Partners LLC2.26790.8068109327310932730
2023-12-31GlobeFlex Capital, L.P.1.11720.238153855900
2023-12-31Dimensional Fund Advisors, Inc.1.03250.0006497722182113.7978
2023-12-31Geode Capital Management, LLC0.92110.0002444046185314.355
2023-12-31Morgan Stanley - Brokerage Accounts0.78060.00013762903746911.0586
2023-12-31Marshall Wace Asset Management Ltd0.72320.002634862213440962.7455
2023-12-31Rice Hall James & Associates, LLC0.68430.0827329870-33796-9.2931
2023-12-31SEI Investments Co0.60540.00229186862112.1743
2023-12-31Two Sigma Advisers, LLC0.59080.0029284800250009.6228
2023-12-31GSA Capital Partners LLP0.54420.0955262337-17292-6.1839
2023-12-31Goldman Sachs Group Inc0.48110.0001231910147766175.6109
2023-12-31Two Sigma Investments LLC0.44630.002121517210743499.7178
Total 48.349713.512523307953+306382+1.3%

3.2. Funds holding Puma Biotechnology Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.63360.00051269607-144600-10.2248
2023-12-31Vanguard Explorer Inv1.61260.015777739000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.21530.0036585850151522.655
2023-12-31Vanguard Strategic Equity Inv1.12110.0354043400
2024-03-29Avantis US Small Cap Value ETF0.59640.014128751500
2023-12-31Acadian Global Small-Cap Equity CIT Cl A0.58270.381628092500
2023-12-31Vanguard Strategic Small-Cap Equity Inv0.47260.066222782700
2024-02-29BlackRock Advantage Small Cap Core Instl0.44660.0382215312-904-0.4181
2024-02-29Fidelity Extended Market Index0.42120.0033203064-21985-9.769
2023-12-31Vanguard VIF Small Co Gr0.4090.056519718100
2023-12-31Federated Hermes MDT SCG Institutional0.33120.1479159667-19451-10.8593
2023-12-31Federated Hermes MDT Small Cap Growth IS0.33120.1485159667-19451-10.8593
2024-02-29SEI Tax-Managed Small/Mid Cap F (SIMT)0.29490.1041142162-20534-12.6211
2024-02-29DFA US Small Cap I0.28290.005513637100
2023-12-31Bridgeway Ultra-Small Company Market0.24730.2778119200-24000-16.7598
2024-03-29Dimensional US Small Cap ETF0.22810.007310993700
2024-03-31BlackRock Extended Equity Market K0.21130.00371018583004441.8359
2024-02-29DFA US Micro Cap I0.19990.00849638400
2023-09-30BlackRock Extended Mkt Composite0.17080.00158231600
2024-02-29GlobeFlex U.S. Micro Cap Equity Cmpst0.16552.114679766-46808-36.9807
Total 11.97423.4295772433-252537-4.4%

3.3. Insider Transactions

Insiders are holding 15.123% of the shares of Puma Biotechnology Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-03Alan H AuerbachSELL413964.49
2024-01-03Alvin F WongSELL77334.49
2024-01-03Maximo F NouguesSELL156824.49
2023-11-07Michael Patrick MillerSELL250002.83
2023-07-03Alan H AuerbachSELL606983.31
2023-07-03Alvin F WongSELL69383.31
2023-07-03Maximo F NouguesSELL146803.31
2023-06-13Troy Edward WilsonSELL270003.45
2023-06-02Alvin F WongSELL2693.45

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Puma Biotechnology Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3050.165+85%0.125+144%0.020+1436%-0.016+105%
Book Value Per Share--1.1090.770+44%0.366+203%0.392+183%1.671-34%
Current Ratio--1.5721.930-19%1.839-15%1.688-7%3.493-55%
Debt To Asset Ratio--0.7680.824-7%0.913-16%0.918-16%0.634+21%
Debt To Equity Ratio--3.3144.939-33%13.288-75%8.517-61%4.864-32%
Dividend Per Share----0%-0%-0%-0%
Eps--0.2540.112+127%0.000+2453500%-0.148+158%-0.625+346%
Free Cash Flow Per Share--0.2160.075+190%-0.118+155%0.026+729%-0.314+245%
Free Cash Flow To Equity Per Share--0.2160.075+190%-0.055+126%-0.097+145%0.130+66%
Gross Profit Margin--0.9700.993-2%1.003-3%1.005-3%1.002-3%
Intrinsic Value_10Y_max--9.992--------
Intrinsic Value_10Y_min---2.444--------
Intrinsic Value_1Y_max--0.217--------
Intrinsic Value_1Y_min---1.091--------
Intrinsic Value_3Y_max--1.250--------
Intrinsic Value_3Y_min---2.565--------
Intrinsic Value_5Y_max--3.004--------
Intrinsic Value_5Y_min---3.246--------
Market Cap241518072.000+14%208737176.000163663444.000+28%148598694.000+40%397938384.200-48%2366015401.900-91%
Net Profit Margin--0.1700.085+101%-0.002+101%-0.147+187%-0.513+402%
Operating Margin--0.2050.142+44%0.127+61%-0.031+115%-0.454+321%
Operating Ratio--0.7950.865-8%0.874-9%1.027-23%1.096-27%
Pb Ratio4.519+14%3.9064.635-16%10.247-62%-47.714+1322%-4.523+216%
Pe Ratio4.922+14%4.25414.079-70%-23.742+658%-4.754+212%-14.874+450%
Price Per Share5.010+14%4.3303.395+28%3.083+40%8.255-48%49.080-91%
Price To Free Cash Flow Ratio5.800+14%5.0134.352+15%18.132-72%-64.801+1393%-53.400+1165%
Price To Total Gains Ratio16.430+14%14.20025.480-44%-75.034+628%64.702-78%7.642+86%
Quick Ratio--1.5681.907-18%1.678-7%1.618-3%4.467-65%
Return On Assets--0.0530.025+114%0.001+4733%-0.029+155%-0.146+375%
Return On Equity--0.2300.126+82%-0.069+130%-0.209+191%-0.355+255%
Total Gains Per Share--0.3050.165+85%0.125+144%0.020+1436%-0.016+105%
Usd Book Value--53442000.00037107500.000+44%17661500.000+203%18893750.000+183%80531250.000-34%
Usd Book Value Change Per Share--0.3050.165+85%0.125+144%0.020+1436%-0.016+105%
Usd Book Value Per Share--1.1090.770+44%0.366+203%0.392+183%1.671-34%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.2540.112+127%0.000+2453500%-0.148+158%-0.625+346%
Usd Free Cash Flow--10410000.0003592250.000+190%-5706750.000+155%1255250.000+729%-15139375.000+245%
Usd Free Cash Flow Per Share--0.2160.075+190%-0.118+155%0.026+729%-0.314+245%
Usd Free Cash Flow To Equity Per Share--0.2160.075+190%-0.055+126%-0.097+145%0.130+66%
Usd Market Cap241518072.000+14%208737176.000163663444.000+28%148598694.000+40%397938384.200-48%2366015401.900-91%
Usd Price Per Share5.010+14%4.3303.395+28%3.083+40%8.255-48%49.080-91%
Usd Profit--12268000.0005397750.000+127%2000.000+613300%-7153800.000+158%-30148250.000+346%
Usd Revenue--72178000.00058909250.000+23%57014000.000+27%60718150.000+19%37325575.000+93%
Usd Total Gains Per Share--0.3050.165+85%0.125+144%0.020+1436%-0.016+105%
 EOD+4 -4MRQTTM+28 -6YOY+29 -55Y+24 -1010Y+21 -13

4.2. Fundamental Score

Let's check the fundamental score of Puma Biotechnology Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154.922
Price to Book Ratio (EOD)Between0-14.519
Net Profit Margin (MRQ)Greater than00.170
Operating Margin (MRQ)Greater than00.205
Quick Ratio (MRQ)Greater than11.568
Current Ratio (MRQ)Greater than11.572
Debt to Asset Ratio (MRQ)Less than10.768
Debt to Equity Ratio (MRQ)Less than13.314
Return on Equity (MRQ)Greater than0.150.230
Return on Assets (MRQ)Greater than0.050.053
Total8/10 (80.0%)

4.3. Technical Score

Let's check the technical score of Puma Biotechnology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.000
Ma 20Greater thanMa 505.392
Ma 50Greater thanMa 1005.662
Ma 100Greater thanMa 2005.056
OpenGreater thanClose4.920
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets230,528
Total Liabilities177,086
Total Stockholder Equity53,442
 As reported
Total Liabilities 177,086
Total Stockholder Equity+ 53,442
Total Assets = 230,528

Assets

Total Assets230,528
Total Current Assets156,185
Long-term Assets74,343
Total Current Assets
Cash And Cash Equivalents 84,585
Short-term Investments 11,354
Net Receivables 48,489
Inventory 7,080
Other Current Assets 4,677
Total Current Assets  (as reported)156,185
Total Current Assets  (calculated)156,185
+/-0
Long-term Assets
Property Plant Equipment 8,647
Intangible Assets 60,871
Long-term Assets Other 2,734
Long-term Assets  (as reported)74,343
Long-term Assets  (calculated)72,252
+/- 2,091

Liabilities & Shareholders' Equity

Total Current Liabilities99,382
Long-term Liabilities77,704
Total Stockholder Equity53,442
Total Current Liabilities
Short-term Debt 38,797
Short Long Term Debt 33,997
Accounts payable 6,889
Other Current Liabilities 53,696
Total Current Liabilities  (as reported)99,382
Total Current Liabilities  (calculated)133,379
+/- 33,997
Long-term Liabilities
Long term Debt 65,659
Capital Lease Obligations 11,834
Long-term Liabilities Other 4,890
Long-term Liabilities  (as reported)77,704
Long-term Liabilities  (calculated)82,383
+/- 4,679
Total Stockholder Equity
Common Stock5
Retained Earnings -1,345,164
Accumulated Other Comprehensive Income -4
Other Stockholders Equity 1,398,605
Total Stockholder Equity (as reported)53,442
Total Stockholder Equity (calculated)53,442
+/-0
Other
Capital Stock5
Cash and Short Term Investments 95,939
Common Stock Shares Outstanding 48,040
Liabilities and Stockholders Equity 230,528
Net Debt 26,905
Net Invested Capital 153,098
Net Working Capital 56,803
Property Plant and Equipment Gross 16,327
Short Long Term Debt Total 111,490



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-30
> Total Assets 
8,615
1,407
2,166
2,291
72
0
0
2
0
2
0
2
2
0
0
2
38
55,398
52,822
44,436
36,497
151,699
151,699
127,984
115,109
104,374
220,253
196,078
172,053
162,758
331,884
302,361
271,624
239,842
205,174
170,892
134,031
252,790
216,624
172,819
181,858
165,525
169,639
227,621
230,723
259,122
331,355
239,858
232,044
234,905
225,529
263,814
261,695
244,220
258,659
259,998
226,287
226,585
200,685
193,651
198,770
222,059
196,257
200,494
203,605
230,528
230,528203,605200,494196,257222,059198,770193,651200,685226,585226,287259,998258,659244,220261,695263,814225,529234,905232,044239,858331,355259,122230,723227,621169,639165,525181,858172,819216,624252,790134,031170,892205,174239,842271,624302,361331,884162,758172,053196,078220,253104,374115,109127,984151,699151,69936,49744,43652,82255,3983820022020200722,2912,1661,4078,615
   > Total Current Assets 
8,615
1,407
2,166
2,291
72
0
0
2
0
2
0
2
2
0
0
2
25
53,663
50,711
41,828
34,117
148,972
148,972
123,437
110,576
96,396
211,663
183,605
160,097
149,379
316,686
287,784
254,663
223,549
189,357
153,749
117,400
236,474
204,634
160,804
119,597
106,394
111,186
170,060
174,411
203,003
256,158
157,609
151,095
166,296
158,681
159,224
159,804
146,139
163,765
167,751
136,923
140,022
117,570
114,280
122,353
134,281
111,753
118,552
125,354
156,185
156,185125,354118,552111,753134,281122,353114,280117,570140,022136,923167,751163,765146,139159,804159,224158,681166,296151,095157,609256,158203,003174,411170,060111,186106,394119,597160,804204,634236,474117,400153,749189,357223,549254,663287,784316,686149,379160,097183,605211,66396,396110,576123,437148,972148,97234,11741,82850,71153,6632520022020200722,2912,1661,4078,615
       Cash And Cash Equivalents 
8,615
1,407
2,166
2,291
72
0
0
2
0
2
0
2
2
0
0
2
25
53,382
50,173
41,002
33,347
137,408
137,400
60,902
51,261
43,044
163,380
55,356
28,263
38,500
155,466
59,837
23,598
31,600
78,219
57,836
52,541
194,500
105,086
80,817
79,717
81,700
78,552
95,912
68,300
108,400
48,800
27,164
58,900
60,000
83,385
90,896
90,082
85,300
95,653
89,848
63,947
63,100
63,913
52,756
77,960
76,200
61,394
60,007
81,800
84,585
84,58581,80060,00761,39476,20077,96052,75663,91363,10063,94789,84895,65385,30090,08290,89683,38560,00058,90027,16448,800108,40068,30095,91278,55281,70079,71780,817105,086194,50052,54157,83678,21931,60023,59859,837155,46638,50028,26355,356163,38043,04451,26160,902137,400137,40833,34741,00250,17353,3822520022020200722,2912,1661,4078,615
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,100
46,618
44,377
40,904
32,734
122,996
125,597
102,800
154,863
222,531
224,177
184,300
102,995
85,952
56,390
35,000
88,894
70,832
26,620
0
0
38,600
59,700
57,000
101,600
90,501
51,500
51,600
17,170
16,376
18,942
8,096
13,397
19,127
23,596
18,975
9,994
7,998
0
4,873
9,823
14,432
3,229
11,354
11,3543,22914,4329,8234,87307,9989,99418,97523,59619,12713,3978,09618,94216,37617,17051,60051,50090,501101,60057,00059,70038,6000026,62070,83288,89435,00056,39085,952102,995184,300224,177222,531154,863102,800125,597122,99632,73440,90444,37746,61827,1000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,612
10,612
14,773
11,294
9,813
13,296
1,760
1,760
1,760
1,760
0
0
0
0
1,179
1,179
0
0
0
3,890
9,670
16,309
21,343
30,982
21,948
90,896
25,346
27,182
28,896
31,542
23,987
27,137
25,543
26,158
30,549
23,799
32,526
27,039
33,987
31,878
42,270
31,164
31,290
28,974
48,489
48,48928,97431,29031,16442,27031,87833,98727,03932,52623,79930,54926,15825,54327,13723,98731,54228,89627,18225,34690,89621,94830,98221,34316,3099,6703,8900001,1791,17900001,7601,7601,7601,76013,2969,81311,29414,77310,61210,612000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
281
538
826
770
952
952
1,144
3,644
2,635
2,253
3,493
4,477
6,292
6,357
5,416
6,888
7,660
8,143
8,782
7,290
6,998
10,654
9,155
9,281
12,997
5,158
3,527
5,080
3,851
3,083
2,953
2,594
2,733
3,308
2,777
2,482
2,702
3,318
3,322
2,984
2,582
3,051
7,158
2,823
1,954
1,953
2,009
3,406
4,677
4,6773,4062,0091,9531,9542,8237,1583,0512,5822,9843,3223,3182,7022,4822,7773,3082,7332,5942,9533,0833,8515,0803,5275,15812,9979,2819,15510,6546,9987,2908,7828,1437,6606,8885,4166,3576,2924,4773,4932,2532,6353,6441,14495295277082653828100000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
1,735
2,111
2,608
2,381
2,727
2,727
4,547
4,533
7,978
8,590
12,473
11,956
13,379
15,198
14,577
16,961
16,293
15,817
17,143
16,631
16,316
11,990
12,015
62,261
59,131
58,453
57,561
56,312
56,119
75,197
82,249
80,949
68,609
66,848
104,590
101,891
98,081
94,894
92,247
89,364
86,563
83,115
79,371
76,417
87,778
84,504
81,942
78,251
74,343
74,34378,25181,94284,50487,77876,41779,37183,11586,56389,36492,24794,89498,081101,891104,59066,84868,60980,94982,24975,19756,11956,31257,56158,45359,13162,26112,01511,99016,31616,63117,14315,81716,29316,96114,57715,19813,37911,95612,4738,5907,9784,5334,5472,7272,7272,3812,6082,1111,735130000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
682
1,057
1,228
1,169
1,479
1,479
1,648
1,619
1,684
1,769
1,941
1,910
2,157
2,412
2,579
2,532
2,383
2,219
5,224
5,180
5,153
5,000
4,888
4,714
4,470
4,320
4,311
4,240
3,963
24,838
24,083
23,398
21,826
21,101
20,353
19,616
18,885
18,117
17,346
16,565
15,773
14,964
14,158
13,335
12,508
11,669
10,891
9,447
8,647
8,6479,44710,89111,66912,50813,33514,15814,96415,77316,56517,34618,11718,88519,61620,35321,10121,82623,39824,08324,8383,9634,2404,3114,3204,4704,7144,8885,0005,1535,1805,2242,2192,3832,5322,5792,4122,1571,9101,9411,7691,6841,6191,6481,4791,4791,1691,2281,05768230000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,760
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000001,760000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
49,379
48,355
47,368
46,382
45,395
44,408
43,421
42,434
41,447
40,461
39,474
78,148
76,144
74,140
72,136
70,133
68,129
66,125
64,121
62,118
60,114
70,610
68,175
65,740
63,305
60,871
60,87163,30565,74068,17570,61060,11462,11864,12166,12568,12970,13372,13674,14076,14478,14839,47440,46141,44742,43443,42144,40845,39546,38247,36848,35549,3790000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,053
1,054
1,380
1,212
1,248
1,249
2,899
2,914
6,294
6,821
10,532
10,046
11,222
12,786
11,998
14,429
13,910
13,598
11,919
11,451
11,163
6,990
7,127
57,547
54,661
6,765
6,868
6,677
7,748
6,938
15,732
16,104
6,322
6,273
6,089
6,131
5,056
4,641
4,768
4,670
4,665
4,030
3,095
2,968
4,660
0
5,311
0
0
005,31104,6602,9683,0954,0304,6654,6704,7684,6415,0566,1316,0896,2736,32216,10415,7326,9387,7486,6776,8686,76554,66157,5477,1276,99011,16311,45111,91913,59813,91014,42911,99812,78611,22210,04610,5326,8216,2942,9142,8991,2491,2481,2121,3801,0541,05300000000000000000
> Total Liabilities 
8,615
1,407
2,166
500
2,249
2
1
2
0
2
2
0
0
0
2
3
362
1,026
10,226
16,398
27,495
22,790
22,790
20,959
20,349
20,387
21,466
29,039
30,450
45,710
27,548
27,583
26,783
33,835
40,231
43,815
42,883
42,966
49,232
52,711
102,690
112,223
112,183
189,322
184,810
224,816
287,884
218,087
214,864
217,442
216,152
240,411
262,148
250,171
242,222
230,529
237,209
229,031
193,540
173,913
176,615
200,451
170,410
170,095
164,863
177,086
177,086164,863170,095170,410200,451176,615173,913193,540229,031237,209230,529242,222250,171262,148240,411216,152217,442214,864218,087287,884224,816184,810189,322112,183112,223102,69052,71149,23242,96642,88343,81540,23133,83526,78327,58327,54845,71030,45029,03921,46620,38720,34920,95922,79022,79027,49516,39810,2261,026362320002202122,2495002,1661,4078,615
   > Total Current Liabilities 
0
0
0
500
2,249
2
1
2
0
2
2
0
0
0
2
3
212
586
9,483
15,542
26,660
21,701
21,701
19,823
19,226
19,271
20,243
27,932
29,359
44,441
26,077
26,099
25,331
32,442
38,905
38,968
37,599
37,461
43,730
47,241
97,252
58,340
58,118
63,530
57,880
67,115
101,398
91,661
88,343
90,837
90,467
94,526
118,197
114,255
140,408
137,900
116,261
109,586
74,789
56,834
59,987
77,484
48,188
60,287
67,362
99,382
99,38267,36260,28748,18877,48459,98756,83474,789109,586116,261137,900140,408114,255118,19794,52690,46790,83788,34391,661101,39867,11557,88063,53058,11858,34097,25247,24143,73037,46137,59938,96838,90532,44225,33126,09926,07744,44129,35927,93220,24319,27119,22619,82321,70121,70126,66015,5429,483586212320002202122,249500000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,477
48,556
120,269
0
0
2,239
2,339
2,516
2,624
2,735
2,852
8,685
17,380
26,077
34,765
3,454
3,574
3,698
3,840
3,988
4,140
4,297
15,792
27,292
38,797
38,79727,29215,7924,2974,1403,9883,8403,6983,5743,45434,76526,07717,3808,6852,8522,7352,6242,5162,3392,23900120,26948,55648,47700000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,477
48,556
120,269
0
0
2,239
0
0
0
0
0
5,714
14,286
22,857
31,429
0
0
0
0
0
0
0
11,332
22,664
33,997
33,99722,66411,332000000031,42922,85714,2865,714000002,23900120,26948,55648,47700000000000000000000000000000000000000000
       Accounts payable 
0
0
0
500
2,249
2
1
2
0
2
0
0
0
0
2
3
212
87
567
2,410
1,018
21,701
482
7,624
9,730
10,692
15,192
18,797
18,448
14,997
12,608
10,444
9,783
17,803
24,837
24,624
20,878
20,035
23,970
24,668
17,644
27,692
23,560
22,336
16,363
20,684
28,878
15,071
9,056
19,183
17,268
11,767
12,528
12,076
10,654
11,166
20,047
11,174
7,412
9,841
14,927
6,440
8,589
7,795
5,061
6,889
6,8895,0617,7958,5896,44014,9279,8417,41211,17420,04711,16610,65412,07612,52811,76717,26819,1839,05615,07128,87820,68416,36322,33623,56027,69217,64424,66823,97020,03520,87824,62424,83717,8039,78310,44412,60814,99718,44818,79715,19210,6929,7307,62448221,7011,0182,41056787212320000202122,249500000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
8,916
13,132
25,642
21,219
21,219
12,199
9,496
8,579
5,051
9,135
10,911
29,444
13,469
15,655
15,548
14,639
14,068
14,344
16,721
17,426
19,760
22,573
79,608
30,648
34,558
41,194
41,517
46,431
70,281
74,251
76,771
69,030
1,000
1,085
2,496
2,481
3,092
3,368
1,978
2,263
63,679
43,153
41,072
66,904
35,302
1,204
1,236
53,696
53,6961,2361,20435,30266,90441,07243,15363,6792,2631,9783,3683,0922,4812,4961,0851,00069,03076,77174,25170,28146,43141,51741,19434,55830,64879,60822,57319,76017,42616,72114,34414,06814,63915,54815,65513,46929,44410,9119,1355,0518,5799,49612,19921,21921,21925,64213,1328,91650000000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150
439
744
856
835
1,089
1,089
1,136
1,123
1,116
1,223
1,107
1,091
1,269
1,471
1,484
1,452
1,393
1,326
4,847
5,284
5,505
5,502
5,470
5,438
53,883
54,065
125,792
126,930
157,701
186,486
126,426
126,521
126,605
125,685
145,885
143,951
135,916
101,814
92,629
120,948
119,445
118,751
117,079
116,628
122,967
122,222
109,808
97,501
77,704
77,70497,501109,808122,222122,967116,628117,079118,751119,445120,94892,629101,814135,916143,951145,885125,685126,605126,521126,426186,486157,701126,930125,79254,06553,8835,4385,4705,5025,5055,2844,8471,3261,3931,4521,4841,4711,2691,0911,1071,2231,1161,1231,1361,0891,0898358567444391500000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,477
48,556
120,269
121,054
151,886
152,841
93,434
94,185
94,962
95,755
96,573
91,714
84,025
76,346
68,706
96,802
97,092
0
0
0
0
0
0
0
0
0000000097,09296,80268,70676,34684,02591,71496,57395,75594,96294,18593,434152,841151,886121,054120,26948,55648,47700000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
439
743
855
835
1,089
1,113
1,136
1,123
1,116
1,223
1,107
1,091
1,269
1,471
1,484
1,452
1,393
1,326
4,847
5,284
5,505
5,502
5,470
5,438
5,406
5,509
5,523
5,876
5,815
9,000
9,000
9,000
9,000
8,000
28,153
31,872
32,342
6,758
6,100
7,235
6,378
6,358
5,414
5,711
12,826
0
12,663
0
0
0012,663012,8265,7115,4146,3586,3787,2356,1006,75832,34231,87228,1538,0009,0009,0009,0009,0005,8155,8765,5235,5095,4065,4385,4705,5025,5055,2844,8471,3261,3931,4521,4841,4711,2691,0911,1071,2231,1161,1231,1361,1131,08983585574343900000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
439
744
856
835
1,089
1,113
1,136
1,123
1,116
1,223
1,107
1,091
1,269
1,471
1,484
1,452
1,393
1,326
4,847
5,284
5,505
5,502
5,470
5,438
5,406
5,509
5,523
5,876
5,815
1,461
1,440
1,664
868
852
1,043
1,056
955
673
836
768
743
472
289
160
0
0
0
0
0
000001602894727437688366739551,0561,0438528681,6641,4401,4615,8155,8765,5235,5095,4065,4385,4705,5025,5055,2844,8471,3261,3931,4521,4841,4711,2691,0911,1071,2231,1161,1231,1361,1131,08983585674443900000000000000000
> Total Stockholder Equity
8,615
1,407
2,166
1,791
-2,177
-2
0
0
0
0
0
2
2
0
-2
-2
-324
54,373
42,595
28,039
9,003
128,909
128,900
107,025
94,760
83,987
198,787
167,039
141,603
117,000
304,336
274,778
244,841
206,000
164,943
127,077
91,148
209,800
167,392
120,108
79,168
53,300
57,456
38,299
45,900
34,306
43,500
21,771
17,200
17,500
9,377
23,403
-453
-6,000
16,437
29,469
-10,922
-2,400
7,145
19,738
22,155
21,600
25,847
30,399
38,742
53,442
53,44238,74230,39925,84721,60022,15519,7387,145-2,400-10,92229,46916,437-6,000-45323,4039,37717,50017,20021,77143,50034,30645,90038,29957,45653,30079,168120,108167,392209,80091,148127,077164,943206,000244,841274,778304,336117,000141,603167,039198,78783,98794,760107,025128,900128,9099,00328,03942,59554,373-324-2-202200000-2-2,1771,7912,1661,4078,615
   Common Stock
300
300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5555555444444444444444444444433333333333333332222000000000000000300300
   Retained Earnings -1,345,164-1,357,432-1,363,228-1,365,354-1,366,755-1,361,149-1,360,789-1,370,160-1,366,757-1,370,981-1,326,309-1,321,103-1,337,631-1,322,637-1,291,174-1,294,569-1,277,636-1,266,437-1,249,552-1,212,128-1,202,041-1,171,346-1,157,145-1,112,811-1,088,466-1,024,388-947,208-869,376-796,511-723,850-658,069-591,472-520,500-458,781-398,364-333,670-281,216-233,733-197,889-159,045-139,251-123,305-109,022-84,592-84,592-62,680-36,821-22,066-10,240-77-72-69-62-56-53-51-46-43-39-35-29-27-23-200-3
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70
69
64,610
64,659
64,858
71,680
213,498
214,673
216,118
218,070
223,232
357,835
365,002
375,451
399,191
638,092
673,505
703,651
726,651
756,383
785,112
814,992
1,006,344
1,036,825
1,067,337
1,109,212
1,142,213
1,170,331
1,195,600
1,217,258
1,236,355
1,255,586
1,271,209
1,283,498
1,295,033
1,303,940
1,314,572
1,322,180
1,331,676
1,337,536
1,355,775
1,360,057
1,364,309
1,377,302
1,380,522
1,383,299
1,388,358
1,391,196
1,393,628
0
0
001,393,6281,391,1961,388,3581,383,2991,380,5221,377,3021,364,3091,360,0571,355,7751,337,5361,331,6761,322,1801,314,5721,303,9401,295,0331,283,4981,271,2091,255,5861,236,3551,217,2581,195,6001,170,3311,142,2131,109,2121,067,3371,036,8251,006,344814,992785,112756,383726,651703,651673,505638,092399,191375,451365,002357,835223,232218,070216,118214,673213,49871,68064,85864,65964,6106970000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
8,318
1,107
2,186
1,814
-2,150
27
34
39
42
46
50
55
58
62
66
70
-247
64,621
64,659
64,858
71,680
0
213,774
216,118
218,070
223,232
357,835
365,002
375,451
398,356
638,092
673,320
703,651
726,651
756,383
785,112
814,992
1,006,344
1,036,814
1,067,337
1,103,559
1,141,762
1,174,598
1,195,441
1,217,258
1,236,355
1,255,575
1,271,209
1,283,498
1,295,033
1,303,940
1,314,572
1,322,180
1,331,627
1,343,885
1,355,775
1,360,057
1,364,309
1,377,302
1,380,522
1,383,299
1,388,350
1,391,196
1,393,628
1,396,173
1,398,605
1,398,6051,396,1731,393,6281,391,1961,388,3501,383,2991,380,5221,377,3021,364,3091,360,0571,355,7751,343,8851,331,6271,322,1801,314,5721,303,9401,295,0331,283,4981,271,2091,255,5751,236,3551,217,2581,195,4411,174,5981,141,7621,103,5591,067,3371,036,8141,006,344814,992785,112756,383726,651703,651673,320638,092398,356375,451365,002357,835223,232218,070216,118213,774071,68064,85864,65964,621-2477066625855504642393427-2,1501,8142,1861,1078,318



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue235,637
Cost of Revenue-62,682
Gross Profit172,955172,955
 
Operating Income (+$)
Gross Profit172,955
Operating Expense-139,690
Operating Income33,26533,265
 
Operating Expense (+$)
Research Development50,382
Selling General Administrative88,427
Selling And Marketing Expenses881
Operating Expense139,690139,690
 
Net Interest Income (+$)
Interest Income2,405
Interest Expense-13,330
Other Finance Cost-75
Net Interest Income-10,850
 
Pretax Income (+$)
Operating Income33,265
Net Interest Income-10,850
Other Non-Operating Income Expenses0
Income Before Tax (EBT)22,67443,856
EBIT - interestExpense = 19,935
22,674
34,921
Interest Expense13,330
Earnings Before Interest and Taxes (EBIT)33,26536,004
Earnings Before Interest and Taxes (EBITDA)44,784
 
After tax Income (+$)
Income Before Tax22,674
Tax Provision-841
Net Income From Continuing Ops3,71721,833
Net Income21,591
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses202,372
Total Other Income/Expenses Net-10,59110,850
 

Technical Analysis of Puma Biotechnology Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Puma Biotechnology Inc. The general trend of Puma Biotechnology Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Puma Biotechnology Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Puma Biotechnology Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 5.05 < 5.65 < 6.055.

The bearish price targets are: 4.3 > 4.14 > 3.66.

Tweet this
Puma Biotechnology Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Puma Biotechnology Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Puma Biotechnology Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Puma Biotechnology Inc. The current macd is -0.08988404.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Puma Biotechnology Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Puma Biotechnology Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Puma Biotechnology Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Puma Biotechnology Inc Daily Moving Average Convergence/Divergence (MACD) ChartPuma Biotechnology Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Puma Biotechnology Inc. The current adx is 12.44.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Puma Biotechnology Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Puma Biotechnology Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Puma Biotechnology Inc. The current sar is 5.84699029.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Puma Biotechnology Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Puma Biotechnology Inc. The current rsi is 42.00. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Puma Biotechnology Inc Daily Relative Strength Index (RSI) ChartPuma Biotechnology Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Puma Biotechnology Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Puma Biotechnology Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Puma Biotechnology Inc Daily Stochastic Oscillator ChartPuma Biotechnology Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Puma Biotechnology Inc. The current cci is -152.59070093.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Puma Biotechnology Inc Daily Commodity Channel Index (CCI) ChartPuma Biotechnology Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Puma Biotechnology Inc. The current cmo is -25.31657365.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Puma Biotechnology Inc Daily Chande Momentum Oscillator (CMO) ChartPuma Biotechnology Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Puma Biotechnology Inc. The current willr is -90.47619048.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Puma Biotechnology Inc Daily Williams %R ChartPuma Biotechnology Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Puma Biotechnology Inc.

Puma Biotechnology Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Puma Biotechnology Inc. The current atr is 0.35501747.

Puma Biotechnology Inc Daily Average True Range (ATR) ChartPuma Biotechnology Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Puma Biotechnology Inc. The current obv is -1,780,457.

Puma Biotechnology Inc Daily On-Balance Volume (OBV) ChartPuma Biotechnology Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Puma Biotechnology Inc. The current mfi is 46.22.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Puma Biotechnology Inc Daily Money Flow Index (MFI) ChartPuma Biotechnology Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Puma Biotechnology Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Puma Biotechnology Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Puma Biotechnology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.000
Ma 20Greater thanMa 505.392
Ma 50Greater thanMa 1005.662
Ma 100Greater thanMa 2005.056
OpenGreater thanClose4.920
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Puma Biotechnology Inc with someone you think should read this too:
  • Are you bullish or bearish on Puma Biotechnology Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Puma Biotechnology Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Puma Biotechnology Inc

I send you an email if I find something interesting about Puma Biotechnology Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Puma Biotechnology Inc.

Receive notifications about Puma Biotechnology Inc in your mailbox!